Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH Highlights
Filter by Topic
ASH 2011 Annual Meeting
ASH 2013 Annual Meeting
ASH 2014 - Castleman's Disease
ASH 2014 - CLL
ASH 2015 - Multiple Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
ASH 2015 – Leukemia
ASH 2017
ASH 2017 - Acute Myeloid Leukemia
ASH 2019 Wrap-up
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
Wayne Kuznar
ASH Highlights
,
Multiple Myeloma
February 2023, Vol 14, No 1
Response to treatment with a regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was greater and minimal residual disease (MRD) was achieved more frequently compared with a regimen of lenalidomide plus dexamethasone (Rd) in the first randomized phase 3 clinical trial dedicated to frail, transplant-ineligible patients with newly diagnosed multiple myeloma.
Read Article
Restrictive Diet May Not Be Necessary for Patients Undergoing HSCT
By
Phoebe Starr
ASH Highlights
,
Hematologic Malignancies
February 2023, Vol 14, No 1
Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.
Read Article
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
By
Phoebe Starr
ASH Highlights
,
Leukemia
,
Lymphoma
February 2023, Vol 14, No 1
A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, is more effective at preventing disease progression and better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that has been the current standard of care for this population of patients.
Read Article
Time-Limited Venetoclax-Based Regimens Show Efficacy in Fit Patients with CLL
By
Phoebe Starr
ASH Highlights
April 2022, Vol 13, No 2
Treatment with time-limited venetoclax (Venclexta)-based combination regimens resulted in superior rates of undetectable minimal residual disease (uMRD) in the peripheral blood at 15 months compared with chemoimmunotherapy (CIT) in fit patients with chronic lymphocytic leukemia (CLL), according to findings from the GAIA (CLL13) clinical trial.
Read Article
Isatuximab plus RVd Combination Achieves High Rates of No MRD in Patients with Multiple Myeloma
By
Phoebe Starr
ASH Highlights
April 2022, Vol 13, No 2
The addition of isatuximab (Sarclisa) to the triplet of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) achieved superior minimal residual disease (MRD) negativity rates versus standard therapy with RVd alone as induction treatment in transplant-eligible patients with newly diagnosed multiple myeloma, according to results of the phase 3 GMMG-HD7 clinical trial presented at the 2021 ASH Annual Meeting and Exposition.
Read Article
Polatuzumab Vedotin plus R-CHP Improves Progression-Free Survival in Newly Diagnosed DLBCL
By
Phoebe Starr
ASH Highlights
April 2022, Vol 13, No 2
The antibody–drug conjugate polatuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL).
Read Article
CAR T-Cell Therapies Show Efficacy in Second-Line Treatment of Large B-Cell Lymphoma
By
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL).
Read Article
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
By
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Results from 2 single-center studies presented at the ASH 2021 Annual Meeting and Exposition showed that nearly 1 in 6 patients with hematologic diseases had no or low antibody response after a second COVID-19 vaccination, but that the mRNA 1273 COVID-19 vaccine induced a strong antibody response in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Read Article
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
By
Wayne Kuznar
ASH Highlights
February 2022, Vol 13, No 1 Online Only
Treatment with the investigational agent mosunetuzumab (RG7828) as monotherapy induced deep remissions in patients with relapsed/refractory follicular lymphoma, according to results of a recent trial presented at the ASH 2021 Annual Meeting and Exposition.
Read Article
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
By
Wayne Kuznar
ASH Highlights
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—The emergence of cellular immunotherapy for a broad array of hematologic malignancies was featured prominently at ASH 2019. The development of adoptive therapy with T-cells that target oncologic malignancies was the subject of the E. Donnall Thomas Lecture “The Long Road to Develop Adoptive Therapy with T Cells That Can Effectively Target Acute Myeloid Leukemia (AML) and Other Malignancies,” delivered by Philip Greenberg, MD, Head, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA.
Read Article
Page 1 of 15
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma